+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Botulinum Toxin In Urology Market Size, Share & Trends Analysis Report By Application (Overactive Bladder, Neurogenic Detrusor Overactivity), By End-use (Hospitals, Urology Clinics), By Region, And Segment Forecasts, 2023 - 2030

  • PDF Icon

    Report

  • 110 Pages
  • October 2023
  • Region: Global
  • Grand View Research
  • ID: 5899650
The global botulinum toxin in urology market size is anticipated to reach USD 1.45 billion by 2030. The market is projected to grow at a CAGR of 6.0% from 2023 to 2030. The demand for botulinum toxin is growing due to a rise in the prevalence of neurogenic bladder, rising geriatric population associated with urinary condition problems and urinary incontinence. For instance, in May 2023, according to the U.S. Census Bureau 2020, around 55.8 million or 16.8% of the population in the U.S. has been classified as older. As a result, the rising geriatric population has led to an increase in urinary condition problems, further leading to market growth.

In addition, in May 2023, according to the Continence Foundation of Australia, urinary incontinence affects about 38% of women and 10% of men in Australia. Thus, the increase in the prevalence of urinary incontinence raised the growth of the market. Urinary incontinence is caused due to constipation, pelvic floor disorders, stroke, and side effects of certain medications.

However, rising investment in R&D by government and private organizations to explore the therapeutic approach of botulinum in the urology sector creates new opportunities for the market. For instance, in July 2022, AbbVie Inc. and Allergan PLC presented more than 30 abstracts, including seven podium presentations at the TOXINS 2022 Conference in New Orleans. It highlighted preclinical research, clinical studies, and real-world utilization data of onabotulinumtoxinA. Thus, increased funding by various institutions boosts market growth.

Botulinum Toxin In Urology Market Report Highlights

  • In terms of application, the overactive bladder segment held the largest market share of 67.14% in 2022 and it is anticipated to register the fastest CAGR over the forecast period. Factors such as abdominal trauma, excessive alcohol consumption, and nerve damage increase the incidence of overactive bladder, further increasing the segment's growth
  • Based on end-use, the hospitals segment held the largest market share of 73.74% in 2022. The growing number of hospitals in developing nations and technological advancements are fueling the market growth of this segment
  • North America region emerged as the leading market region in 2022, holding the largest share of 37.41%. The region's robust healthcare infrastructure, skilled healthcare professionals, and advanced medical facilities contribute to the market growth in the region.
  • The Asia Pacific region is anticipated to register the fastest CAGR of 7.3% over the forecast period owing to the increased prevalence of chronic diseases and diabetes


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Market Definitions
1.3. Information Procurement
1.3.1. Purchased Database
1.3.2. Internal Database
1.3.3. Secondary Sources & Third-Party Perspectives
1.3.4. Primary Research
1.3.5. Details of Primary Research
1.4. Information Analysis
1.4.1. Data Analysis Models
1.5. Market Formulation & Data Visualization
1.5.1. Commodity Flow Analysis
1.5.1.1. Approach 1: Commodity flow approach
1.6. Data Validation & Publishing
1.7. Global Market: CAGR Calculation
1.8. List of Secondary Sources
1.9. List of Primary Sources
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Trends and Outlook
3.3. Market Dynamics
3.4. Market Restraint Analysis
3.5. Business Environment Analysis
3.5.1. SWOT Analysis; By Factor (Political & Legal, Economic and Technological)
3.5.2. Porter’s Five Forces Analysis
3.6. Economic Impact Analysis
Chapter 4. Application Business Analysis
4.1. Botulinum Toxin In Urology Market, By Application: Key Takeaways
4.2. Botulinum Toxin In Urology Market: Application Movement & Market Share Analysis, 2022 & 2030
4.3. Overactive Bladder
4.3.1. Global Overactive Bladder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Neurogenic Detrusor Overactivity
4.4.1. Global Neurogenic Detrusor Overactivity Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. End-Use Business Analysis
5.1. Botulinum Toxin In Urology Market, By End-use: Key Takeaways
5.2. Botulinum Toxin In Urology Market: End-use Movement & Market Share Analysis, 2022 & 2030
5.3. Hospitals
5.3.1. Global Hospitals Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Urology Clinics
5.4.1. Global Urology Clinics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Regional Business Analysis
6.1. Regional Market Snapshot
6.2. North America
6.2.1. North America Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
6.2.2. U.S.
6.2.2.1. U.S. Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
6.2.3. Canada
6.2.3.1. Canada Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
6.3. Europe
6.3.1. Europe Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
6.3.2. Germany
6.3.2.1. Germany Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
6.3.3. UK
6.3.3.1. UK Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
6.3.4. France
6.3.4.1. France Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
6.3.5. Italy
6.3.5.1. Italy Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
6.3.6. Spain
6.3.6.1. Spain Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
6.3.7. Denmark
6.3.7.1. Denmark Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
6.3.8. Sweden
6.3.8.1. Sweden Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
6.3.9. Norway
6.3.9.1. Norway Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
6.4. Asia Pacific
6.4.1. Asia Pacific Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
6.4.2. Japan
6.4.2.1. Japan Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
6.4.3. China
6.4.3.1. China Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
6.4.4. India
6.4.4.1. India Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
6.4.5. South Korea
6.4.5.1. South Korea Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
6.4.6. Australia
6.4.6.1. Australia Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
6.4.7. Thailand
6.4.7.1. Thailand Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
6.5. Latin America
6.5.1. Latin America Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
6.5.2. Brazil
6.5.2.1. Brazil Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
6.5.3. Mexico
6.5.3.1. Mexico Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
6.5.4. Argentina
6.5.4.1. Argentina Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
6.6. MEA
6.6.1. MEA Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
6.6.2. South Africa
6.6.2.1. South Africa Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
6.6.3. Saudi Arabia
6.6.3.1. Saudi Arabia Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
6.6.4. UAE
6.6.4.1. UAE Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
6.6.5. Kuwait
6.6.5.1. Kuwait Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Company Categorization
7.2. Strategy Mapping
7.3. Company Profiles/Listing
7.3.1. AbbVie Inc.
7.3.1.1. Overview
7.3.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.1.3. Product Benchmarking
7.3.1.4. Strategic Initiatives
7.3.2. Merz Pharma
7.3.2.1. Overview
7.3.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.2.3. Product Benchmarking
7.3.2.4. Strategic Initiatives
7.3.3. Ipsen Pharma
7.3.3.1. Overview
7.3.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.3.3. Product Benchmarking
7.3.3.4. Strategic Initiatives
7.3.4. GALDERMA
7.3.4.1. Overview
7.3.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.4.3. Product Benchmarking
7.3.4.4. Strategic Initiatives
7.3.5. Allergan PLC
7.3.5.1. Overview
7.3.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.5.3. Product Benchmarking
7.3.5.4. Strategic Initiatives
7.3.6. Sun Pharmaceutical Industries Ltd.
7.3.6.1. Overview
7.3.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.6.3. Product Benchmarking
7.3.6.4. Strategic Initiatives
7.3.7. Biovencer Healthcare Pvt Ltd
7.3.7.1. Overview
7.3.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.7.3. Product Benchmarking
7.3.7.4. Strategic Initiatives
List of Tables
Table 1 List of Abbreviations
Table 2 Global Botulinum Toxin In Urology Market, by application, 2018-2030 (USD Million)
Table 3 Global Botulinum Toxin In Urology Market, by end-use, 2018-2030 (USD Million)
Table 4 Global Botulinum Toxin In Urology Market, by region, 2018-2030 (USD Million)
Table 5 North America Botulinum Toxin In Urology Market, by country, 2018-2030 (USD Million)
Table 6 North America Botulinum Toxin In Urology Market, by application, 2018-2030 (USD Million)
Table 7 North America Botulinum Toxin In Urology Market, by End-use, 2018-2030 (USD Million)
Table 8 U.S. Botulinum Toxin In Urology Market, by application, 2018-2030 (USD Million)
Table 9 U.S. Botulinum Toxin In Urology Market, by End-use, 2018-2030 (USD Million)
Table 10 Canada Botulinum Toxin In Urology Market, by application, 2018-2030 (USD Million)
Table 11 Canada Botulinum Toxin In Urology Market, by End-use, 2018-2030 (USD Million)
Table 12 Europe Botulinum Toxin In Urology Market, by country, 2018-2030 (USD Million)
Table 13 Europe Botulinum Toxin In Urology Market, by application, 2018-2030 (USD Million)
Table 14 Europe Botulinum Toxin In Urology Market, by end-use, 2018-2030 (USD Million)
Table 15 Germany Botulinum Toxin In Urology Market, by application, 2018-2030 (USD Million)
Table 16 Germany Botulinum Toxin In Urology Market, by end-use, 2018-2030 (USD Million)
Table 17 UK Botulinum Toxin In Urology Market, by application, 2018-2030 (USD Million)
Table 18 UK Botulinum Toxin In Urology Market, by end-use, 2018-2030 (USD Million)
Table 19 France Botulinum Toxin In Urology Market, by application, 2018-2030 (USD Million)
Table 20 France Botulinum Toxin In Urology Market, by end-use, 2018-2030 (USD Million)
Table 21 Italy Botulinum Toxin In Urology Market, by application, 2018-2030 (USD Million)
Table 22 Italy Botulinum Toxin In Urology Market, by end-use, 2018-2030 (USD Million)
Table 23 Spain Botulinum Toxin In Urology Market, by application, 2018-2030 (USD Million)
Table 24 Spain Botulinum Toxin In Urology Market, by end-use, 2018-2030 (USD Million)
Table 25 Denmark Botulinum Toxin In Urology Market, by application, 2018-2030 (USD Million)
Table 26 Denmark Botulinum Toxin In Urology Market, by end-use, 2018-2030 (USD Million)
Table 27 Sweden Botulinum Toxin In Urology Market, by application, 2018-2030 (USD Million)
Table 28 Sweden Botulinum Toxin In Urology Market, by end-use, 2018-2030 (USD Million)
Table 29 Norway Botulinum Toxin In Urology Market, by application, 2018-2030 (USD Million)
Table 30 Norway Botulinum Toxin In Urology Market, by end-use, 2018-2030 (USD Million)
Table 31 Asia Pacific Botulinum Toxin In Urology Market, by country, 2018-2030 (USD Million)
Table 32 Asia Pacific Botulinum Toxin In Urology Market, by application, 2018-2030 (USD Million)
Table 33 Asia Pacific Botulinum Toxin In Urology Market, by end-use, 2018-2030 (USD Million)
Table 34 China Botulinum Toxin In Urology Market, by application, 2018-2030 (USD Million)
Table 35 China Botulinum Toxin In Urology Market, by end-use, 2018-2030 (USD Million)
Table 36 Japan Botulinum Toxin In Urology Market, by application, 2018-2030 (USD Million)
Table 37 Japan Botulinum Toxin In Urology Market, by end-use, 2018-2030 (USD Million)
Table 38 India Botulinum Toxin In Urology Market, by application, 2018-2030 (USD Million)
Table 39 India Botulinum Toxin In Urology Market, by end-use, 2018-2030 (USD Million)
Table 40 South Korea Botulinum Toxin In Urology Market, by application, 2018-2030 (USD Million)
Table 41 South Korea Botulinum Toxin In Urology Market, by end-use, 2018-2030 (USD Million)
Table 42 Australia Botulinum Toxin In Urology Market, by application, 2018-2030 (USD Million)
Table 43 Australia Botulinum Toxin In Urology Market, by end-use, 2018-2030 (USD Million)
Table 44 Thailand Botulinum Toxin In Urology Market, by application, 2018-2030 (USD Million)
Table 45 Thailand Botulinum Toxin In Urology Market, by end-use, 2018-2030 (USD Million)
Table 46 Latin America Botulinum Toxin In Urology Market, by country, 2018-2030 (USD Million)
Table 47 Latin America Botulinum Toxin In Urology Market, by application, 2018-2030 (USD Million)
Table 48 Latin America Botulinum Toxin In Urology Market, by end-use, 2018-2030 (USD Million)
Table 49 Brazil Botulinum Toxin In Urology Market, by application, 2018-2030 (USD Million)
Table 50 Brazil Botulinum Toxin In Urology Market, by end-use, 2018-2030 (USD Million)
Table 51 Mexico Botulinum Toxin In Urology Market, by application, 2018-2030 (USD Million)
Table 52 Mexico Botulinum Toxin In Urology Market, by end-use, 2018-2030 (USD Million)
Table 53 Argentina Botulinum Toxin In Urology Market, by application, 2018-2030 (USD Million)
Table 54 Argentina Botulinum Toxin In Urology Market, by end-use, 2018-2030 (USD Million)
Table 55 Middle East & Africa Botulinum Toxin In Urology Market, by application, 2018-2030 (USD Million)
Table 56 Middle East & Africa Botulinum Toxin In Urology Market, by end-use, 2018-2030 (USD Million)
Table 57 South Africa Botulinum Toxin In Urology Market, by application, 2018-2030 (USD Million)
Table 58 South Africa Botulinum Toxin In Urology Market, by end-use, 2018-2030 (USD Million)
Table 59 Saudi Arabia Botulinum Toxin In Urology Market, by application, 2018-2030 (USD Million)
Table 60 Saudi Arabia Botulinum Toxin In Urology Market, by end-use, 2018-2030 (USD Million)
Table 61 UAE Botulinum Toxin In Urology Market, by application, 2018-2030 (USD Million)
Table 62 UAE Botulinum Toxin In Urology Market, by end-use, 2018-2030 (USD Million)
Table 63 Kuwait Botulinum Toxin In Urology Market, by application, 2018-2030 (USD Million)
Table 64 Kuwait Botulinum Toxin In Urology Market, by end-use, 2018-2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain-based sizing & forecasting
Fig. 6 Market formulation & validation
Fig. 7 Botulinum Toxin In Urology Market Segmentation
Fig. 8 Market snapshot, 2022
Fig. 9 Market Trends & outlook
Fig. 10 Market driver relevance analysis (Current & future impact)
Fig. 11 Market restraint relevance analysis (Current & future impact)
Fig. 12 Swot analysis, by factor (political & legal, economic and technological)
Fig. 13 Porter’s Five Forces analysis
Fig. 14 Global Botulinum Toxin In Urology Market: Application Outlook Key Takeaways
Fig. 15 Global Botulinum Toxin In Urology Market: Application Movement Analysis
Fig. 16 Global Overactive Bladder Market, 2018-2030 (USD Million)
Fig. 17 Global Neurogenic Detrusor Overactivity Market, 2018-2030 (USD Million)
Fig. 18 Global Botulinum Toxin In Urology Market: End-use Outlook Key Takeaways
Fig. 19 Global Botulinum Toxin In Urology Market: End-use Movement Analysis
Fig. 20 Global Hospitals Market, 2018-2030 (USD Million)
Fig. 21 Global Urology Clinics Market, 2018-2030 (USD Million)
Fig. 22 Regional Marketplace: Key Takeaways
Fig. 23 Regional Outlook, 2022 & 2030
Fig. 24 Global Botulinum Toxin In Urology Market: Region Movement Analysis
Fig. 25 North America Botulinum Toxin In Urology Market, 2018-2030 (USD Million)
Fig. 26 U.S. Botulinum Toxin In Urology Market, 2018-2030 (USD Million)
Fig. 27 Canada Botulinum Toxin In Urology Market, 2018-2030 (USD Million)
Fig. 28 Europe Botulinum Toxin In Urology Market, 2018-2030 (USD Million)
Fig. 29 Germany Botulinum Toxin In Urology Market, 2018-2030 (USD Million)
Fig. 30 UK Botulinum Toxin In Urology Market, 2018-2030 (USD Million)
Fig. 31 France Botulinum Toxin In Urology Market, 2018-2030 (USD Million)
Fig. 32 Italy Botulinum Toxin In Urology Market, 2018-2030 (USD Million)
Fig. 33 Spain Botulinum Toxin In Urology Market, 2018-2030 (USD Million)
Fig. 34 Spain Botulinum Toxin In Urology Market, 2018-2030 (USD Million)
Fig. 35 Denmark Botulinum Toxin In Urology Market, 2018-2030 (USD Million)
Fig. 36 Sweden Botulinum Toxin In Urology Market, 2018-2030 (USD Million)
Fig. 37 Norway Botulinum Toxin In Urology Market, 2018-2030 (USD Million)
Fig. 38 Asia Pacific Botulinum Toxin In Urology Market, 2018-2030 (USD Million)
Fig. 39 Japan Botulinum Toxin In Urology Market, 2018-2030 (USD Million)
Fig. 40 China Botulinum Toxin In Urology Market, 2018-2030 (USD Million)
Fig. 41 India Botulinum Toxin In Urology Market, 2018-2030 (USD Million)
Fig. 42 Australia Botulinum Toxin In Urology Market, 2018-2030 (USD Million)
Fig. 43 South Korea Botulinum Toxin In Urology Market, 2018-2030 (USD Million)
Fig. 44 Thailand Botulinum Toxin In Urology Market, 2018-2030 (USD Million)
Fig. 45 Latin America Botulinum Toxin In Urology Market, 2018-2030 (USD Million)
Fig. 46 Brazil Botulinum Toxin In Urology Market, 2018-2030 (USD Million)
Fig. 47 Mexico Botulinum Toxin In Urology Market, 2018-2030 (USD Million)
Fig. 48 Argentina Botulinum Toxin In Urology Market, 2018-2030 (USD Million)
Fig. 49 Middle East and Africa Botulinum Toxin In Urology Market, 2018-2030 (USD Million)
Fig. 50 South Africa Botulinum Toxin In Urology Market, 2018-2030 (USD Million)
Fig. 51 Saudi Arabia Botulinum Toxin In Urology Market, 2018-2030 (USD Million)
Fig. 52 UAE Botulinum Toxin In Urology Market, 2018-2030 (USD Million)
Fig. 53 Kuwait Botulinum Toxin In Urology Market, 2018-2030 (USD Million)

Companies Mentioned

  • AbbVie Inc.
  • Merz Pharma
  • Ipsen Pharma
  • GALDERMA
  • Allergan PLC
  • Sun Pharmaceutical Industries Ltd.
  • Biovencer Healthcare Pvt Ltd

Methodology

Loading
LOADING...

Table Information